课题基金 / 基金详情

Warfarin vs Aspirin in Reduced Ejection Fraction -STAT

Warfarin vs Aspirin in Reduced Ejection Fraction -STAT
华法林与阿司匹林在射血分数降低方面的比较 -STAT
批准号:
7430249
负责人:
JOHN L THOMPSON
金额:
$20.0万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-30 至 2008-02-29

项目摘要

项目成果

JOHN L THOMPSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
WARCEF-STAT and WARCEF-CLIN are two separate but highly coordinated units which together constitute WARCEF, a two-arm (1:1) double-blind randomized multicenter clinical trial (target enrollment 2860 patients at 70 clinical sites) designed to test the primary null hypothesis of no difference between warfarin (INR 2.5-3, target 2.75) and aspirin (325 mg/day) in 3-5 year survival for the composite endpoint death or stroke or intracerebral hemorrhage among patients with low (<=30%) cardiac Left Ventricular Ejection Fraction (LVEF). Prespecified secondary hypotheses are tested for subgroups of women and African Americans, and for the endpoint of stroke alone. Prespecified tertiary hypotheses are tested by amalgamating data from WARCEF and another trial (WATCH). The goals of WARCEF-STAT are: 1) to conduct, efficiently integrate, and be responsible for all WARCEF data management, double-blinding, medication management, quality control, and reporting operations. 2) to specify, conduct and be responsible for all interim, safety, and final statistical analyses for WARCEF and for the reporting of these results. 3) to transmit to the Clinical Coordinating Center (CCC) in a timely fashion all of the data which the principal investigator of WARCEF-CLIN needs to meet his responsibilities in terms of ensuring patient safety and directing all clinical operations. Goal 1 is accomplished by integrating a Data Management Center with substantial experience in cardiac trials and an anticoagulation unit which is successfully conducting an ongoing double blind warfarin-aspirin study (WARSS). The double-blind algorithm used in WARSS to fabricate INRs for patients on active aspirin will be recalibrated and revalidated for the WARCEF target range before WARCEF begins. Goal 2 is achieved by a statistical analysis unit that is experienced in stroke, cardiac, and other clinical trials. Goal 3 is ensured by an Operations Committee of WARCEF-STAT and WARCEF-CLIN investigators and senior coordinators which meets frequently under tightly specified and controlled communication protocols.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biostatistics and Data Management Core
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)
Clinical Trial of High Dose CoQ10 in ALS-QALS-=STAT
海外基金